reports
Tenet Healthcare Corp: 2 directors
Two Directors at Tenet Healthcare Corp sold 13,967 shares at between 205.107USD and 205.200USD. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Magnificent Seven's Turn to Shine We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass). We will maintain our bullish intermediate-term outlook as long as market dynamics remain healthy and the S&P 500 (SPX) is above 6200 (up from 6028-6059). Additionally, we discussed since our 10/14/25 Compass how our near-term bullish outlook remains intact as long as the SPX holds above 6550-6569, which coincided with the ...
TSLA TESLA INC
THC TENET HEALTHCARE CORPORATION
NVDA NVIDIA CORPORATION
HCA HCA HEALTHCARE INC
HAL HALLIBURTON COMPANY
GOOGL ALPHABET INC. CLASS A
CYH COMMUNITY HEALTH SYSTEMS INC.
MAGS MAGAL SECURITY SYSTEMS LTD.
RIGN TRANSOCEAN LTD.
AAPL APPLE INC.
SDRL SEADRILL LTD.
VAL VALARIS LTD
BORR BORR DRILLING LTD
ARKK ARK INNOVATION ETF
NE NOBLE CORP (NEW)
ARDT ARDENT HEALTH PARTNERS INC
Moody's Ratings assigns Ba3 and B2 ratings to Tenet Healthcare's propo...
Moody's Ratings (Moody's) assigned Ba3 rating to Tenet Healthcare Corporation's ("Tenet") proposed offering of senior secured first lien notes due 2032 and B2 rating to the senior unsecured notes proposed offering due 2033. Tenet intends to use the net proceeds from this offering for general corpora...
Moody's Ratings assigns Baa2 rating to HCA's proposed senior unsecured...
Moody's Ratings (Moody's) assigned Baa2 ratings to HCA Inc.'s ("HCA") proposed offering of backed senior unsecured notes of up to $3.25 billion with various maturities. HCA intends to use the net proceeds from this offering for general corporate purposes including repayment of outstanding borrowings...
Moody's Ratings upgrades HCA Inc.'s senior unsecured debt rating to Ba...
Moody's Ratings (Moody's) upgraded the ratings of HCA Inc.'s ("HCA") senior unsecured debt (which includes senior unsecured debentures/notes, backed senior unsecured notes and the senior unsecured bank credit facility) to Baa2 from Baa3. We also upgraded the backed commercial paper rating to P-2 fro...
Moody's Ratings affirms Tenet Healthcare Corporation's Ba3 CFR; revis...
Moody's Ratings (Moody's) affirmed the ratings of Tenet Healthcare Corporation ("Tenet") including the Ba3 Corporate Family Rating (CFR), Ba3-PD Probability of Default Rating (PDR), Ba3 ratings of senior secured first and second lien notes and B2 rating of senior unsecured notes. At the same time, w...
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Reve...
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition of scPharmaceuticals is expected to diversify and accelerate MannKind’s double-digit revenue growth, driven by FUROSCIX® (furosemide injection), an innovative therapy for edema due to chronic heart failure and chronic kidney disease. The transaction will strengthen MannKind’s co...
- Gary Brode
- Gary Brode
- Gary Brode
- Gary Brode
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and...
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet needUpfront cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash Upfront cash payment represents ...
scPharmaceuticals Receives Notice of Allowances of Multiple US Patent ...
scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111 BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, announced today that it has received five Notices of Allowance from the United States Patent and Trademark Office (USPTO) for patent applications covering their latest furosemide formulation, SCP-111. The SCP-111 formulation is the subject of a supplemental NDA expected to...
scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results a...
scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update Generated net FUROSCIX® revenue of $16 million in the second quarter of 2025; up 99% over Q2 2024 Doses shipped to patients increased 45% over Q1 2025 and 117% over Q2 2024 Launch of FUROSCIX in chronic kidney disease Autoinjector remains on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $40.8 million as of June 30, 2025 Investor conference call and webcast today, Thursday, August 7th, at 4:30pm ...
scPharmaceuticals to Announce Second Quarter 2025 Financial Results Af...
scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025 Management to host conference call and webcast, after-market on August 7, 2025, at 4:30 p.m. ET BURLINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, August 7, 2025, to discuss the financial results for the ...
Moody's Ratings assigns P-3 rating to HCA Inc.'s commercial paper prog...
Moody's Ratings (Moody's) today assigned a Prime-3 (P-3) rating to the new backed senior unsecured commercial paper program of HCA Inc. ("HCA"). At the same time, we affirmed HCA's existing ratings including the Baa3 ratings of senior unsecured debentures/notes, backed senior unsecured notes and the...
- Dave Nicoski
- Ross LaDuke
RCKY ROCKY BRANDS
PZZA PAPA JOHN'S INTERNATIONAL INC.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
MU MICRON TECHNOLOGY INC.
MSA MSA SAFETY INC.
MPC MARATHON PETROLEUM CORPORATION
MCHP MICROCHIP TECHNOLOGY INCORPORATED
KOP KOPPERS HOLDINGS INC.
GPC GENUINE PARTS COMPANY
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CVGW CALAVO GROWERS INC.
BEN FRANKLIN RESOURCES INC.
AAP ADVANCE AUTO PARTS INC.
MEG. MEG ENERGY CORP.
FSLR FIRST SOLAR INC.
KALU KAISER ALUMINUM CORPORATION
PVH PVH CORP.
NHC NATIONAL HEALTHCARE CORP.
ELF E.L.F. BEAUTY INC.
DK DELEK US HOLDINGS INC
SCPH SCPHARMACEUTICALS INC
MTW MANITOWOC COMPANY INC.
TTEC TTEC HOLDINGS INC.
ADNT ADIENT PLC
ULBI ULTRALIFE
ELAN ELANCO ANIMAL HEALTH INC.
OCGN OCUGEN INC
ITOS ITEOS THERAPEUTICS
ETWO E2OPEN PARENT HOLDINGS INC (A)
PAX PATRIA INVESTMENTS
VAL VALARIS LTD
DINO HOLLYFRONTIER CORP
NE NOBLE CORP (NEW)
ADCT ADC THERAPEUTICS SA
SVV SAVERS VALUE VILLAGE INC
GUTS FRACTYL HEALTH INC
LRCX LAM RESEARCH CORPORATION
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Expecting a Test of All-Time Highs The market remains relentlessly strong, shrugging off the latest "bearish" headline regarding Moody's U.S. debt downgrade on Friday. This is exactly what we would expect to happen in a bull market, particularly during this "lockout rally," and helps confirm our bullish outlook. To recap, we have been short-term bullish since our 4/22/25 Compass -- when the SPX was testing 5100-5120 support -- but we upgraded our intermediate-term outlook to bullish as well, as...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.